More

FDA-REGISTERED 503B OUTSOURCING FACILITY

Advanced, automated technologies provide high-quality, cGMP-compliant products with minimal human intervention and no hoods.

We are an FDA-registered 503B outsourcing facility that
uses advanced automated technologies to provide
high-quality cGMP-compliant products with minimal
human intervention and no hoods.

Ordering at your fingertips

Our platform makes ordering simple and secure. Keep your focus on the patients, minimize admin time.
REQUEST ACCESS TODAY!

Meeting and exceeding quality demands

Our aseptic manufacturing process uses advanced automation in the compounding, sterilizing, filling and sealing of finished product. Blow-fill-seal (BFS) and other automated technologies produce sterile products, and help reduce the chance of contamination.

FDA-REGISTERED 503B OUTSOURCING FACILITY

Every SterRx® product meets cGMP-level standard release testing requirements.
All finished compounded drug batches are tested for sterility, endotoxin, pH, appearance and potency prior to release.

ADVANCED AUTOMATION. NO HOODS.

Highly advanced, technological equipment is everywhere: drugs are compounded, filled and sealed in our sterile, automated environment. These processes offer consistent, high-quality product with a reduced risk of contamination, superior production speed and capacity.

PEACE OF MIND COMPLEMENTS PATIENT CARE

A consistent product manufactured with minimal human interaction
can help reduce the risk of contamination and human error.

Precise expiry dating

Other compounded products may use beyond-use dating. We use a more precise statement of product viability: expiration dating. Our customers receive a precise expiration date via our in-house stability testing that includes product testing in real time.

OFFERING YOU MORE WITH LESS HUMAN INTERVENTION

Contact SterRx® at 1-844-319-7799 or email customerservice@SterRx.com
to learn how ready-to-use 503B-compounded products can benefit your facility

SterRx is a registered trademark of SterRx, LLC.

Products compounded by SterRx in accordance with Section 503B are statutorily exempt from FDA’s
drug approval and adequate directions for use requirements in FDCA Sections 505 and 502(f)(1).
SterRx compounded formulations are not FDA-approved or reviewed by FDA for safety or efficacy.

Automation is used in compounding, sterilizing, filling and sealing of the finished product. Post-
production processes such as labeling and packing are performed manually.